Melanoma Coverage from Every Angle

Alexander M.M. Eggermont, MD, PhD, on Adjuvant Therapy for High-Risk Melanoma

Posted: Saturday, October 20, 2018

Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanomamelanoma and the current treatment landscape recommend in light of such data as results on dabrafenib plus trametinib vs anti–PD-1 treatments (nivolumab or pembrolizumab) and the new standard for wild-type disease.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.